Table 3 Baseline characteristics after propensity-score matching
Characteristics | ALL (N = 712) N (%) | CRT (N = 356) N (%) | CT (N = 356) N (%) | p-value |
|---|---|---|---|---|
Age | 0.934 | |||
< 60 | 205 (28.8%) | 102 (28.7%) | 103 (28.9%) | |
≥ 60 | 507 (71.2%) | 254 (71.3%) | 253 (71.1%) | |
Sex | >0.999 | |||
Female | 374 (52.5%) | 187 (52.5%) | 187 (52.5%) | |
Male | 338 (47.5%) | 169 (47.5%) | 169 (47.5%) | |
Primary tumor site | 0.926 | |||
Intrahepatic bile duct | 78 (11.0%) | 38 (10.7%) | 40 (11.2%) | |
Extrahepatic bile duct | 285 (40.0%) | 141 (39.6%) | 144 (40.5%) | |
Gallbladder | 349 (49.0%) | 177 (49.7%) | 172 (48.3%) | |
T stage | 0.971 | |||
T1 | 72 (10.1%) | 36 (10.1%) | 36 (10.1%) | |
T2 | 258 (36.2%) | 132 (37.1%) | 126 (35.4%) | |
T3 | 288 (40.4%) | 142 (39.9%) | 146 (41.0%) | |
T4 | 94 (13.2%) | 46 (12.9%) | 48 (13.5%) | |
N stage | >0.999 | |||
N0 | 384 (53.9%) | 192 (53.9%) | 192 (53.9%) | |
N1 | 322 (45.2%) | 161 (45.2%) | 161 (45.2%) | |
Nx | 6 (0.84%) | 3 (0.9%) | 3 (0.9%) | |
Tumor size | 0.755 | |||
< 5 cm | 456 (64.0%) | 226 (63.5%) | 230 (64.6%) | |
≥ 5 cm | 256 (36.0%) | 130 (36.5%) | 126 (35.4%) | |
# of removed lymph nodes | 0.951 | |||
0 | 163 (22.9%) | 84 (23.6%) | 79 (22.2%) | |
1–3 | 205 (28.8%) | 100 (28.1%) | 105 (29.5%) | |
≥ 4 | 329 (46.2%) | 164 (46.1%) | 165 (46.3%) | |
NA | 15 (2.1%) | 8 (2.2%) | 7 (2.0%) | |
Grade | 0.939 | |||
I: Well differentiated | 79 (11.1%) | 38 (10.7%) | 41 (11.5%) | |
II: Moderately differentiated | 306 (43.0%) | 156 (43.8%) | 150 (42.1%) | |
III: Poorly differentiated | 255 (35.8%) | 127 (35.7%) | 128 (36.0%) | |
IV: Undifferentiated; anaplastic | 14 (2.0%) | 8 (2.2%) | 6 (1.7%) | |
NA | 58 (8.1%) | 27 (7.6%) | 31 (8.7%) |